FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225164047> ?p ?o ?g. }

• W4225164047 endingPage "41" @default.
• W4225164047 startingPage "32" @default.
• W4225164047 abstract "Pheochromocytomas and paragangliomas (PPGLs) have a heterogeneous prognosis, the basis of which remains unclear. We, therefore, assessed disease-specific survival (DSS) and potential predictors of progressive disease in patients with PPGLs and head/neck paragangliomas (HNPGLs) according to the presence or absence of metastases.This retrospective study included 582 patients with PPGLs and 57 with HNPGLs. DSS was assessed according to age, location and size of tumours, recurrent/metastatic disease, genetics, plasma metanephrines and methoxytyramine.Among all patients with PPGLs, multivariable analysis indicated that apart from older age (HR = 5.4, CI = 2.93-10.29, P < 0.0001) and presence of metastases (HR = 4.8, CI = 2.41-9.94, P < 0.0001), shorter DSS was also associated with extra-adrenal tumour location (HR = 2.6, CI = 1.32-5.23, P = 0.0007) and higher plasma methoxytyramine (HR = 1.8, CI = 1.11-2.85, P = 0.0170) and normetanephrine (HR = 1.8, CI = 1.12-2.91, P = 0.0160). Among patients with HNPGLs, those with metastases presented with longer DSS compared to patients with metastatic PPGLs (33.4 versus 20.2 years, P < 0.0001) and only plasma methoxytyramine (HR = 13, CI = 1.35-148, P = 0.0380) was an independent predictor of DSS. For patients with metastatic PPGLs, multivariable analysis revealed that apart from older age (HR = 6.2, CI = 3.20-12.20, P < 0.0001), shorter DSS was associated with the presence of synchronous metastases (HR = 4.9, CI = 2.78-8.80, P < 0.0001), higher plasma methoxytyramine (HR = 2.4, CI = 1.44-4.14, P = 0.0010) and extensive metastatic burden (HR = 2.1, CI = 1.07-3.79, P = 0.0290).DSS among patients with PPGLs/HNPGLs relates to several presentations of the disease that may provide prognostic markers. In particular, the independent associations of higher methoxytyramine with shorter DSS in patients with HNPGLs and metastatic PPGLs suggest the utility of this biomarker to guide individualized management and follow-up strategies in affected patients." @default.
• W4225164047 created "2022-05-01" @default.
• W4225164047 creator A5005313542 @default.
• W4225164047 creator A5005679973 @default.
• W4225164047 creator A5007794291 @default.
• W4225164047 creator A5013015930 @default.
• W4225164047 creator A5014771501 @default.
• W4225164047 creator A5029003117 @default.
• W4225164047 creator A5041910578 @default.
• W4225164047 creator A5046768397 @default.
• W4225164047 creator A5047413937 @default.
• W4225164047 creator A5048446979 @default.
• W4225164047 creator A5051607812 @default.
• W4225164047 creator A5059545146 @default.
• W4225164047 creator A5068457694 @default.
• W4225164047 creator A5068868243 @default.
• W4225164047 creator A5069344737 @default.
• W4225164047 creator A5090455680 @default.
• W4225164047 date "2022-07-01" @default.
• W4225164047 modified "2023-10-16" @default.
• W4225164047 title "Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma" @default.
• W4225164047 cites W1965134014 @default.
• W4225164047 cites W1982777876 @default.
• W4225164047 cites W1986376069 @default.
• W4225164047 cites W2007599332 @default.
• W4225164047 cites W2010599828 @default.
• W4225164047 cites W2032516847 @default.
• W4225164047 cites W2048001604 @default.
• W4225164047 cites W2052953554 @default.
• W4225164047 cites W2057275256 @default.
• W4225164047 cites W2061662711 @default.
• W4225164047 cites W2081855169 @default.
• W4225164047 cites W2088868003 @default.
• W4225164047 cites W2091744291 @default.
• W4225164047 cites W2099532184 @default.
• W4225164047 cites W2109546471 @default.
• W4225164047 cites W2116888810 @default.
• W4225164047 cites W2142599772 @default.
• W4225164047 cites W2159956365 @default.
• W4225164047 cites W2297275786 @default.
• W4225164047 cites W2396030111 @default.
• W4225164047 cites W2428470344 @default.
• W4225164047 cites W2517374546 @default.
• W4225164047 cites W2585589460 @default.
• W4225164047 cites W2610430650 @default.
• W4225164047 cites W2617490862 @default.
• W4225164047 cites W2626337139 @default.
• W4225164047 cites W267486205 @default.
• W4225164047 cites W2762556367 @default.
• W4225164047 cites W2886601036 @default.
• W4225164047 cites W2912667865 @default.
• W4225164047 cites W2979839239 @default.
• W4225164047 cites W3007888461 @default.
• W4225164047 cites W3014338479 @default.
• W4225164047 cites W3024533433 @default.
• W4225164047 cites W3086182333 @default.
• W4225164047 cites W3158395279 @default.
• W4225164047 cites W3199508038 @default.
• W4225164047 cites W4250364331 @default.
• W4225164047 cites W43616094 @default.
• W4225164047 doi "https://doi.org/10.1016/j.ejca.2022.03.032" @default.
• W4225164047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35500459" @default.
• W4225164047 hasPublicationYear "2022" @default.
• W4225164047 type Work @default.
• W4225164047 citedByCount "14" @default.
• W4225164047 countsByYear W42251640472022 @default.
• W4225164047 countsByYear W42251640472023 @default.
• W4225164047 crossrefType "journal-article" @default.
• W4225164047 hasAuthorship W4225164047A5005313542 @default.
• W4225164047 hasAuthorship W4225164047A5005679973 @default.
• W4225164047 hasAuthorship W4225164047A5007794291 @default.
• W4225164047 hasAuthorship W4225164047A5013015930 @default.
• W4225164047 hasAuthorship W4225164047A5014771501 @default.
• W4225164047 hasAuthorship W4225164047A5029003117 @default.
• W4225164047 hasAuthorship W4225164047A5041910578 @default.
• W4225164047 hasAuthorship W4225164047A5046768397 @default.
• W4225164047 hasAuthorship W4225164047A5047413937 @default.
• W4225164047 hasAuthorship W4225164047A5048446979 @default.
• W4225164047 hasAuthorship W4225164047A5051607812 @default.
• W4225164047 hasAuthorship W4225164047A5059545146 @default.
• W4225164047 hasAuthorship W4225164047A5068457694 @default.
• W4225164047 hasAuthorship W4225164047A5068868243 @default.
• W4225164047 hasAuthorship W4225164047A5069344737 @default.
• W4225164047 hasAuthorship W4225164047A5090455680 @default.
• W4225164047 hasBestOaLocation W42251640471 @default.
• W4225164047 hasConcept C126322002 @default.
• W4225164047 hasConcept C126894567 @default.
• W4225164047 hasConcept C142724271 @default.
• W4225164047 hasConcept C143998085 @default.
• W4225164047 hasConcept C167135981 @default.
• W4225164047 hasConcept C2776734335 @default.
• W4225164047 hasConcept C2779134260 @default.
• W4225164047 hasConcept C2779161898 @default.
• W4225164047 hasConcept C2779505177 @default.
• W4225164047 hasConcept C2779512018 @default.
• W4225164047 hasConcept C71924100 @default.
• W4225164047 hasConcept C90924648 @default.
• W4225164047 hasConceptScore W4225164047C126322002 @default.

• next